Mobile

A Randomized, Open-Label Study of Oral CEP-701 Administered in Sequence With Standard Chemotherapy to Patients With Relapsed Acute Myeloid Leukemia (AML) Expressing FLT-3 Activating Mutations

Mise à jour : Il y a 4 ans
Référence : EUCTR2005-002258-23

Femme et Homme

  • | Pays :
    • -
  • | Organes :
    • -
  • | Spécialités :
    • -

Extrait

The primary objective is to determine whether CEP 701 treatment given in sequence with induction chemotherapy increases the proportion of patients with relapsed acute myeloid leukemia (AML) who achieve a second complete remission (CR) or a CR with incomplete platelet recovery (CRp).

Critère d'inclusion

  • Relapsed Acute Myeloid Leukaemia (AML) expressing FLT-3 activating mutations

Liens